GDRXGoodRx Holdings, Inc.

1. Aug 5, 2026Pharma Direct and Subscription Revenue Increased 76% and 39%, Respectively, Year-Over-Year.Earnings release · press release
2. May 6, 2026Pharma Direct Revenue Increased 82% Year-Over-Year in the First Quarter.Earnings release · press release
3. Apr 24, 2026Chief Accounting Officer Appointment On April 23, 2026, the Board of Directors (the “Board”) of GoodRx Holdings, Inc. (the “Company”) appointed Thomas Chan, Vice President, Corporate Controller of the Company as the Company’s Chief Accounting Officer and designated Mr. Chan as the principal accounting officer of the …Director or officer change · Form 8-K
4. Apr 3, 2026Departure of Director On March 31, 2026, Ian T. Clark notified GoodRx Holdings, Inc. (the “Company”) of his decision to resign as a member of the Company’s Board of Directors (the “Board“), including his service on the Board’s Nominating & Governance Committee, effective as of March 31, 2026.Director or officer change · Form 8-K
5. Mar 27, 2026Chief Accounting Officer Resignation On March 24, 2026, Romin Nabiey submitted his resignation as Chief Accounting Officer of GoodRx Holdings, Inc. (the “Company”), effective April 3, 2026 in order to pursue other opportunities.Director or officer change · Form 8-K
6. Mar 18, 2026On March 14, 2026, the Audit and Risk Committee of the Board of Directors of GoodRx Holdings, Inc. (the “Company”), following a competitive proposal process, approved the appointment of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, and …Auditor change · Form 8-K
7. Mar 6, 2026Compensatory Arrangements of Certain Executive Officers On March 3, 2026, the Board of Directors (the “Board”) of GoodRx Holdings, Inc. (the “Company”), upon the recommendation of the Compensation Committee of the Board approved a discretionary cash bonus for 2025 performance in the amount of $72,918 for Romin Nabiey …Director or officer change · Form 8-K
8. Feb 27, 2026Departure of Director On February 26, 2026, Dipanjan Deb notified GoodRx Holdings, Inc. (the “Company”) of his decision to resign as a member of the Company’s Board of Directors, effective as of February 26, 2026.Director or officer change · Form 8-K
9. Feb 25, 2026Fourth Quarter and Full Year 2025 Revenue and Adjusted EBITDA Results In-line with Previous Guidance.Earnings release · press release
10. Dec 12, 2025On December 9, 2025, the Board of Directors of GoodRx Holdings, Inc. (the “Company”) approved the entry by GoodRx, Inc. (a subsidiary of the Company) into retention bonus letter agreements (the “Retention Bonus Agreements”) with each of Wendy Barnes, Chief Executive Officer and President of the Company, and Chris …Director or officer change · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.